Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma
Sponsor: Rznomics, Inc.
Summary
This study is to evaluate the safety, tolerability, efficacy and immunogenicity of RZ-001 in combination with Valganciclovir (VGCV) and Atezolizumab/Bevacizumab when given to subjects with human telomerase reverse transcriptase (hTERT)-positive HCC.
Official title: A Phase 1b/2a, Open-label, Multicenter, Randomized, Dose Escalation Study Evaluating the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
45
Start Date
2024-12-18
Completion Date
2027-10
Last Updated
2025-07-29
Healthy Volunteers
No
Conditions
Interventions
RZ-001 Dose 1
RZ-001 Dose 1 and VGCV, Atezolizumab/Bevacizumab
RZ-001 Dose 2
RZ-001 Dose 2 and VGCV, Atezolizumab/Bevacizumab
RZ-001 Dose 3
RZ-001 Dose 3 and VGCV, Atezolizumab/Bevacizumab
Locations (9)
Pusan National University Yangsan Hospital
Busan, South Korea
Kyungpook National University Hospital
Daegu, South Korea
Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, South Korea
Gangnam Severance Hospital
Seoul, South Korea
Kangbuk Samsung Medical Center
Seoul, South Korea
Korea University Guro Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital
Seoul, South Korea